Mining and analysis of the ADE signals of avapritinib based on FAERS database
- VernacularTitle:基于美国FAERS数据库挖掘与分析阿伐替尼ADE信号
- Author:
Ying HU
1
;
Jianping LI
1
;
Bin TANG
1
;
Qiao DING
1
Author Information
1. Dept. of Neurology and Critical Care Medicine，the Third Affiliated Hospital of Zunyi Medical University/Zunyi First People’s Hospital，Guizhou Zunyi 563000，China
- Publication Type:Journal Article
- Keywords:
avapritinib;
adverse drug event;
proportional imbalance method;
signal mining;
adverse drug reaction
- From:
China Pharmacy
2023;34(13):1622-1626
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To provide reference for clinically safe application of avapritinib. METHODS The adverse drug event （ADE） reports of avapritinib from January 9th，2020，to September 30th，2022 were collected from FDA Adverse Event Reporting System （FAERS） database. For data mining and analysis，reporting odds ratio （ROR） method and proportional reporting ratio （PRR） method in the proportional imbalance method were utilized. RESULTS A total of 10 895 ADE reports with avapritinib as the main suspect drug were gathered，and 201 ADE signals involving 19 systematic organ classifications were found after eliminating invalid signals. The instruction of the drugs did not mention any of the ADE，including tinnitus，dementia，chilly limbs， the reduction of blood iron，the reduction of blood sugar，fever，the reduction of vitamin D and vitamin B12，as well as all ADE in the 2 SOCs of musculoskeletal and connective tissue illnesses，diseases of the reproductive system，and diseases of the breast. The majority of the ADE reports 670 cases with complete drug information were for the nervous system （230 cases，accounting for 34.33%） and ocular organ （277 cases，accounting for 41.34%）. Compared with other systems，daily dose and treatment course showed significant effects on ADE of neurological system and ocular organ （P＜0.05），and the patient’s age had a significant impact on the ADE of the nervous system （P＜0.05）. CONCLUSIONS A greater incidence of ADE after using avapritinib is present in patients older than 65 with a daily dose of 300 mg/d and a treatment period lasting between 31 and 90 days； patients receiving a daily dose of 300 mg/d and a treatment regimen lasting 31 to 90 days are more likely to experience ADE of the ocular organ. Attention should be given to the aberrant symptoms of the patient’s eyes and nervous system throughout clinical use of avapritinib，and prompt intervention should be given.
